newsfilter
← Latest News
ACCESS Newswire·

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors Meg Flippin, Benzinga Staff WriterCARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa